# US 8,278,295 B2 · Amino-heterocyclic compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,295 B2
- Document ID: US8278295B2
- Status: Granted
- Kind: B2
- Application number: 12/693,480
- Filed: 2010-01-26
- Published: 2010-07-29
- Granted: 2012-10-02
- Earliest claimed: 2009-01-26
- Assignees: Pfizer Inc.
- Inventors: Michelle M. Claffey; Christopher J. Helal; Patrick R. Verhoest
- Web page: https://patentgrep.com/patent/US8278295B2

## CPC

- C07D 487/04: Ortho-condensed systems
- A61K 31/13: Amines {(A61K31/04 takes precedence)}
- A61K 31/27: of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/473: ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, A, and n are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.

## Claims

### Claim 1

A compound of Formula (I),
or a pharmaceutically acceptable salt thereof, wherein:
R1 is selected from the group consisting of
(i) hydrogen,
(ii) (C1-C4)alkyl,
(iii) (C2-C4)alkenyl,
(iv) (C2-C4)alkynyl,
(v) (C1-C4)alkoxy,
(vi) (C1-C4)haloalkyl,
(vii) (C3-C6)cycloalkyl, optionally substituted with one to three substituents, the substituents being independently selected from the group consisting of (C1-C4)alkyl, (C1-C4)alkoxy, halo, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, cyano, carboxy, and carbamoyl,
(viii) 4 to 10 member heterocycloalkyl, optionally substituted with one to three substituents, the substituents being independently selected from the group consisting of (C1-C4)alkyl, (C1-C4)alkoxy, halo, (C1-C4)haloalkyl, (C1-C4) haloalkoxy, cyano, carboxy, and carbamoyl,
(ix) aryl, optionally substituted with one to three substituents, the substituents being independently selected from the group consisting of (C1-C4)alkyl, (C1-C4)alkoxy, halo, (C1-C4)haloalkyl, (C1-C4) haloalkoxy, cyano, carboxy, and carbamoyl, and
(x) heteroaryl, optionally substituted with one to three substituents, the substituents being independently selected from the group consisting of (C1-C4)alkyl, (C1-C4)alkoxy, halo, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, cyano, carboxy, and carbamoyl;
R2 is selected from the group consisting of hydrogen, (C1-C4)alkyl, (C1-C4) haloalkyl, cyano, and (C3-C6)cycloalkyl;
R3 is selected from the group consisting of (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6) alkynyl, (C3-C8)cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, each of which optionally may be substituted with one to three substituents, the substituents being independently selected from the group consisting of (C1-C4)alkyl, (C1-C4)alkoxy, halo, and (C1-C4)haloalkyl;
n is 1 or 2;
A is —CR4R5— or —CHRa—CHRb—;
R4 is selected from the group consisting of
(i) hydrogen,
(ii) (C1-C7)alkyl,
(iii) (C3-C8)cycloalkyl,
(iv) 4 to 10 member heterocycloalkyl,
(v) aryl, optionally substituted with one to three substituents, the substituents being independently selected from the group consisting of (C1-C4)alkyl, (C1-C4)alkoxy, halo, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, (C3-C6) cycloalkyl, cyano, carboxy, and carbamoyl,
(vi) heteroaryl, optionally substituted with one to three substituents, the substituents being independently selected from the group consisting of (C1-C4) alkyl, (C1-C4) alkoxy, halo, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, (C3-C6)cycloalkyl, cyano, carboxy, and carbamoyl, and
(vii) LR6, wherein:
L is selected from the group consisting of —CH2—, —NR7—, and —O—;
R6 is aryl, heteroaryl, (C1-C8)alkyl, (C3-C8)cycloalkyl, 4 to 10 member heterocycloalkyl, or (C1-C6)alkoxy, each of which optionally may be substituted with one to three substituents, the substituents being independently selected from the group consisting of (C1-C4)alkyl, (C1-C4) alkoxy, halo, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, (C3-C6)cycloalkyl, cyano, carboxy, and carbamoyl; and
R7 is hydrogen, methyl or ethyl;
R5 is selected from the group consisting of hydrogen, hydroxyl, (C1-C4)alkoxy, halogen, and (C1-C6)alkyl; or R4 and R5, together with the carbon to which they are attached, form a cycloalkyl or heterocycloalkyl ring that optionally incorporates an oxo group and is optionally substituted with (C1-C8)alkyl, (C3-C8) cycloalkyl, halo, (C1-C8) alkoxy, or (C1-C3)haloalkyl;
Ra is (C1-C4)alkoxy or R8—O—C(O)—, wherein R8 is (C1-C4)alkyl; and
Rb is aryl, heteroaryl, or heterocycloalkyl, optionally substituted with halo, (C1-C8) alkyl, (C3-C8)cycloalkyl, (C1-C8)alkoxy, or (C1-C3) haloalkyl; or Ra and Rb, together with the carbons to which they are attached, form a cycloalkyl or heterocycloalkyl ring that optionally incorporates an oxo group and is optionally substituted with (C1-C8) alkyl, (C3-C8) cycloalkyl, halo, (C1-C8)alkoxy, or (C1-C3)haloalkyl.

### Claim 2 (depends on 1)

The compound of claim 1, wherein:
R1 is selected from the group consisting of
(i) (C1-C4)alkyl,
(ii) (C3-C6)cycloalkyl,
(iii) (C1-C4)haloalkyl,
(iv) 4 to 10 member heterocycloalkyl, optionally substituted with one to three substituents, the substituents being independently selected from the group consisting of (C1-C4)alkyl, (C1-C4)alkoxy, halo, (C1-C4)haloalkyl, (C1-C4) haloalkoxy, cyano, carboxy, and carbamoyl,
(v) aryl, optionally substituted with one to three substituents, the substituents being independently selected from the group consisting of (C1-C4)alkyl, (C1-C4)alkoxy, halo, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, cyano, carboxy, and carbamoyl, and
(vi) heteroaryl, optionally substituted with one to three substituents, the substituents being independently selected from the group consisting of (C1-C4)alkyl, (C1-C4)alkoxy, halo, (C1-C4) haloalkoxy, cyano, carboxy, and carbamoyl;
R2 is selected from the group consisting of hydrogen, (C1-C4)alkyl, (C1-C4) haloalkyl, cyano, and cyclopropyl;
R4 is selected from the group consisting of
(i) hydrogen,
(ii) aryl, optionally substituted with one to three substituents, the substituents being independently selected from the group consisting of (C1-C4)alkyl, (C1-C4)alkoxy, halo, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, (C3-C6) cycloalkyl, cyano, carboxy, and carbamoyl,
(iii) heteroaryl, optionally substituted with one to three substituents, the substituents being independently selected from the group consisting of (C1-C4) alkyl, (C1-C4) alkoxy, halo, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, (C3-C6)cycloalkyl, cyano, carboxy, and carbamoyl, and
(iv) LR6, wherein:
L is selected from the group consisting of —CH2—, —NR7—, and —O—; and
R6 is aryl or heteroaryl, each of which optionally may be substituted with one to three substituents, the substituents being independently selected from the group consisting of (C1-C4)alkyl, (C1-C4)alkoxy, halo, (C1-C4) haloalkyl, (C1-C4)haloalkoxy, (C3-C6)cycloalkyl, cyano, carboxy, and carbamoyl;
R5 is selected from the group consisting of hydrogen, hydroxyl, (C1-C4)alkoxy, halo, and (C1-C6)alkyl; or R4 and R5, together with the carbon to which they are attached, form a cyclic ketone; and
Rb is aryl or heteroaryl, optionally substituted with halo, (C1-C3) alkyl, or (C1-C3) haloalkyl; or Ra and Rb, together with the carbons to which they are attached, form a cycloalkyl or heterocycloalkyl ring that optionally incorporates an oxo group and is optionally substituted with (C1-C8)alkyl, (C3-C8)cycloalkyl, halo, (C1-C8)alkoxy, or (C1-C3) haloalkyl.

### Claim 3 (depends on 2)

The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein:
R1 is (C1-C4)alkyl, (C3-C6)cycloalkyl, or phenyl;
R2 is hydrogen;
R3 is selected from the group consisting of isopropyl, cyclobutyl, cyclopentyl, tetrahydrofuranyl, and tetrahydropyranyl;
A is —CR4R5—; and
L is —CH2— or —O—.

### Claim 4 (depends on 3)

The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein:
R1 is methyl, ethyl, cyclopropyl or phenyl;
R4 is selected from the group consisting of hydrogen, phenyl, pyridinyl, pyrimidinyl, quinolinyl, pyrazinyl, pyridazinyl, phthalazinyl, quinazolinyl, naphthyridinyl, quinoxalinyl, isoquinolinyl, benzofuranyl, dihydrobenzofuranyl, each of which optionally may be substituted with one to three substituents, the substituents being independently selected from the group consisting of (C1-C4)alkyl, (C1-C4)alkoxy, halo, (C3-C6)cycloalkyl, carbamoyl, and LR6;
R5 is selected from the group consisting of hydrogen, methyl, hydroxy, and halo; or R4 and R5, together with the carbon to which they are attached form benzopyranone; and
R6 is phenyl, pyrimidinyl, pyridinyl, pyrazinyl, quinoxalinyl, phthalazinyl, pyridazinyl, quinazolinyl, naphthyridinyl, isoquinolinyl, quinolinyl, benzofuranyl, each of which optionally may be substituted with one to three substitutents, the substitutents being independently selected from the group consisting of (C1-C4)alkyl, (C1-C4)alkoxy, halo, (C1-C4)haloalkyl, (C1-C4)haloalkoxy, and cyano.

### Claim 5 (depends on 4)

The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein:
R1 is methyl or ethyl;
n is 1;
R3 is cyclopentyl or tetrahydro-2H-pyranyl;
R4 is pyrimidinyl or LR6;
R5 is hydrogen, methyl, hydroxy, or fluoro;
L is —O—; and
R6 is optionally substituted phenyl.

### Claim 6 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
R1 is methyl, ethyl, cyclopropyl or phenyl;
R2 is hydrogen;
R3 is selected from the group consisting of isopropyl, cyclobutyl, cyclopentyl, and tetrahydro-2H-pyran-4-yl;
n is 1;
A is —CHRa—CHRb—;
Ra is methoxy or R8—O—C(O)—, wherein R8 is methyl; and
Rb is phenyl, optionally substituted with halo; or Ra and Rb, together with the carbons to which they are attached, form a dihydroquinolone, optionally substituted with halo.

### Claim 7 (depends on 1)

The compound of claim 1, selected from the group consisting of:
1-cyclopentyl-6-[(1R)-1-(3-pyrimidin-2-ylazetidin-1-yl)ethyl]-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
1-cyclopentyl-6-{(1R)-1-[3-(pyrimidin-2-yloxy) azetidin-1-yl]ethyl}-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
1-cyclopentyl-6-[(1R)-1-(3-pyridin-2-ylazetidin-1-yl)ethyl]-1,5-dihydro-4H-pyrazol [3,4-d]pyrimidin-4-one;
1-cyclopentyl-6-[(1R)-1-(3-pyridin-4-ylazetidin-1-yl)ethyl]-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
1-cyclopentyl-6-[(1R)-1-(3-pyridin-3-ylazetidin-1-yl)ethyl]-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
1-cyclopentyl-6-[(1R)-1-(3-pyrimidin-5-ylazetidin-1-yl)ethyl]-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
1-cyclopentyl-6-[(1R)-1-(3-pyridazin-3-ylazetidin-1-yl)ethyl]-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
1-cyclopentyl-6-{(1R)-1-[3(pyrimidin-5-ylmethyl)azetidin-1-yl]ethyl}-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
1-cyclopentyl-6-[(1R)-1-(3-pyrimidin-4-ylazetidin-1-yl)ethyl]-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
1-cyclopentyl-6-{(1R)-1-[3-(2-methylpyrimidin-4-yl)azetidin-1-yl]ethyl}-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
1-cyclopentyl-6-[(1R)-1-(3-quinolin-2-ylazetidin-1-yl)ethyl]-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
1-cyclopentyl-6-{(1R)-1-[(3R)-3-(pyrimidin-2-yloxy)pyrrolidin-1-yl]ethyl}-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
1-cyclopentyl-6-{(1R)-1-[(3S)-3-(pyrimidin-2-yloxy)pyrrolidin-1-yl]ethyl}-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
1-cyclopentyl-6-[(1R)-1-{3-[(6-methylpyridin-3-yl)methyl]azetidin-1-yl}ethyl]-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
1-cyclopentyl-6-[(1R)-1-(3-pyrimidin-2-ylpyrrolidin-1-yl)ethyl]-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
1-cyclopentyl-6-{(1R)-1-[3-(5-methylpyrimidin-2-yl)azetidin-1-yl]ethyl}-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
1-cyclopentyl-6-{(1R)-1-[3-(5-cyclopropylpyrimidin-2-yl)azetidin-1-yl]ethyl}-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
1-cyclopentyl-6-{(1R)-1-[3-(4,6-dimethylpyrimidin-2-yl)azetidin-1-yl]ethyl}-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
1-cyclopentyl-6-{(1R)-1-[3-(4-methylpyrimidin-2-yl)azetidin-1-yl]ethyl}-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
1-cyclopentyl-6-{(1R)-1-[3-(3fluorobenzyl)azetidin-1-yl]ethyl}-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
(3aR,9bR)-2-[(1R)-1-(1-cyclopentyl-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)ethyl]-1,2,3,3a,5,9b-hexahydro-4H-pyrrolo[3,4-c]quinolin-4-one;
6-{(1R)-1-[3-(6-bromopyridin-2-yl)pyrrolidin-1-yl]ethyl}-1-cyclopentyl-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
(3aR,9bR)-8-chloro-2-[(1R)-1-(1-cyclopentyl-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)ethyl]-1,2,3,3a,5,9b-hexahydro-4H-pyrrolo[3,4-c]quinolin-4-one;
1-cyclopentyl-6-[(1R)-1-(3-phenylpyrrolidin-1-yl)ethyl]-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
1-cyclopentyl-6-{(1R)-1-[3-(2,3-dimethoxyphenyl)pyrrolidin-1-yl]ethyl}-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
4-({1-[(1R)-1-(1-cyclopentyl-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)ethyl]azetidin-3-yl}oxy)benzonitrile;
1-cyclopentyl-6-{(1R)-1-[3-(3-methylphenoxy)azetidin-1-yl]ethyl}-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
1-cyclopentyl-6-{(1R)-1-[3-(3-methoxyphenoxy)azetidin-1-yl]ethyl}-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
1-cyclopentyl-6-{(1R)-1-[3-(3-methoxyphenyl)-3-methylpyrrolidin-1-yl]ethyl}-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
6-{(1R)-1-[3-(2-chlorophenyl)pyrrolidin-1-yl]ethyl}-1-cyclopentyl-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
1-cyclopentyl-6-{(1R)-1-[3-(2-fluorophenyl)pyrrolidin-1-yl]ethyl}-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
1-cyclopentyl-6-{(1R)-1-[3-(4-fluorophenyl)pyrrolidin-1-yl]ethyl}-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
6-{(1R)-1-[3-(3-chlorophenyl)pyrrolidin-1-yl]ethyl}-1-cyclopentyl-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
1-cyclopentyl-6-[(1R)-1-(3-pyridin-4-ylpyrrolidin-1-yl)ethyl]-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
1-cyclopentyl-6-{(1R)-1-[(3R)-3-(2-methylphenoxy)pyrrolidin-1-yl]ethyl}-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
6-{(1R)-1-[3-(3-chlorophenoxy)azetidin-1-yl]ethyl}-1-cyclopentyl-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
6-{(1S)-1-[(3R)-3-(2-chlorophenoxy)pyrrolidin-1-yl]ethyl}-1-cyclopentyl-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
1-cyclopentyl-6-{(1R)-1-[3-(pyridin-3-yloxy)azetidin-1-yl]ethyl}-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
1-cyclopentyl-6-{(1R)-1-[3-(2,5-dichlorophenoxy)azetidin-1-yl]ethyl}-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
4-{1-[(1R)-1-(1-cyclopentyl-4-oxo-4,5-dihydro-1H-pyrazolo [3,4-d]pyrimidin-6-yl) ethyl]pyrrolidin-3-yl}—N,N-dimethylbenzamide;
1-cyclopentyl-6-{(1R)-1-[3-(2,5-dimethcmphenyl)pyrrolidin-1-yl]ethyl}-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
1-cyclopentyl-6-{(1R)-1-[(3R)-3-(2-methoxphenoxy)pyrrolidin-1-yl]ethyl}-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
6-[(1R)-1-(3-benzylazetidin-1-yl)ethyl]-1-cyclopentyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one;
N-cyclobutyl-3-{1-[(1R)-1-(1-cyclopentyl-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)ethyl]pyrrolidin-3-yl}benzamide;
1-cyclopentyl-6-{(1R)-1-[3-(3,4-difluorophenoxy)azetidin-1-yl]ethyl}-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
6-{(1R)-1-[3-(4-chlorophenoxy)azetidin-1-yl]ethyl}-1-cyclopentyl-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
1-cyclopentyl-6-{(1R)-1-[3-(4-methoxyphenoxy)azetidin-1-yl]ethyl}-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
1-cyclopentyl-6-{(1R)-1-[(3S)-3-(2-methoxyphenoxy)pyrrolidin-1-yl]ethyl}-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
2-({(3R)-1-[(1R)-1-(1-cyclopentyl-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)ethyl]pyrrolidin-3-yl}oxy)benzonitrile;
1-cyclopentyl-6-[(1R)-1-{3-[4-(trifluoromethyl)phenoxy]azetidin-1-yl}ethyl]-1, 5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
methyl(3R,4S)-1-[(1R)-1-(1-cyclopentyl-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)ethyl]-4-(4-fluorophenyl)pyrrolidine-3-carboxylate;
1-cyclopentyl-6-{(1R)-1-[(3S,4R)-3-methoxy-4-phenylpyrrolidin-1-yl]ethyl}-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
1-cyclopentyl-6-[(1R)-1-{3[3-(trifluoromethyl)phenoxy]azetidin-1-yl}ethyl]-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
6-{(1R)-1-[3-(2-chloro-5-fluorophenoxy)azetidin-1-yl]ethyl}-1-cyclopentyl-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
1-[(1R)-1-(1-cyclopentyl-4-oxo-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl)ethyl]spiro[azetidine-3,2′-chromen]-4′(3′H)-one;
1-cyclopentyl-6-{(1R)-1-[3-(4-fluorophenoxy)azetidin-1-yl]ethyl}-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1)

The compound of claim 1, selected from the group consisting of:
6-{(1R)-1-[3-(4-methylpyridin-2-yl)azetidin-1-yl]ethyl}-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
6-[cyclopropyl(3-phenoxyazetidin-1-yl)methyl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
2-fluoro-5-[(1-{1-[4-oxo-1-(tetrahydro-2H-pyran-4-yl)-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-6-yl]ethyl}azetidin-3-yl)oxy]benzonitrile;
6-[(1R)-1-(3-quinolin-2-ylazetidin-1-yl)ethyl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
6-{(1R)-1-[3-(6-methylpyridin-2-yl)azetidin-1-yl]ethyl}-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo [3,4-c]pyrimidin-4-one;
6-{(1R)-1-[3-(4-fluorophenoxy)azetidin-1-yl]ethyl}-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
6-{(1R)-1-[3-(5-chloropyrimidin-2-yl)azetidin-1-yl]ethyl}-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
6-[(1R)-1-(3-phenylazetidin-1-yl)ethyl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
6-[(1R)-1-(3-pyrazin-2-ylazetidin-1-yl)ethyl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
6-[(1R)-1-(3-pyrimidin-2-ylazetidin-1-yl)ethyl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
6-[(1R)-1-(3-pyridin-2-ylazetidin-1-yl)ethyl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
6-[(1R)-1-(3-pyridin-4-ylazetidin-1-yl)ethyl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
6-[(1R)-1-(3-pyridin-3-ylazetidin-1-yl)ethyl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
6-[(1R)-1-(3-pyrimidin-5-ylazetidin-1-yl)ethyl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
6-[(1R)-1-(3-pyridazin-3-ylazetidin-1-yl)ethyI]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
6-{(1R)-1-[3-(2-methylpyrimidin-4-yl)azetidin-1-yl]ethyl}-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H- pyrazolo [3,4-d]pyrimidin-4-one;
6-{(1R)-1-[3-(3-fluorobenzyl)azetidin-1-yl]ethyl}-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
6-[(1R)-1-(3-phenoxyazetidin-1-ypethyl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
6-{(1R)-1-[3-(6-methylpyridin-2-yl)azetidin-1-yl]propyl}-1-(tetrahydro-2H-pyran-4-yl )-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
6-[(1-(3-pyridin-2-ylazetidin-1-yl)propyI]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
6-{(1R)-1-[3-(5-methylpyrimidin-2-yl)azetidin-1-yl]propyl}-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
6-{(1R)-1-[3-(5-chloropyrimidin-2-yl)azetidin-1-yl]propyl}-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
6-{(1R)-1-[3-(pyrimidin-2-ylmethyl)azetidin-1-yl]ethyl}-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
6-{(1R)-1-[3-(5-methylpyrimidin-2-yl)azetidin-1-yl]ethyl}-1-(tetrahydro-2H-pyran-4-yl-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
6-{(1R)-1-[3-(5-cyclopropylpyrimidin-2-yl)azetidin-1-yl]ethyl}-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
6-{(1R)-1-[3-(4,6-dimethylpyrimidin-2-yl)azetidin-1-yl]ethyl}-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one; and
6-{(1R)-1-[3-(4-methylpyrimidin-2-yl)azetidin-1-yl]ethyl}-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one;
or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 1)

The compound of claim 1, selected from the group consisting of:
1-cyclobutyl-6-{(1R)-1-[3-(pyrimidin-2yloxy)azetidin-1-yl]ethyl}-1,5-dihydro-4H-pyrazolo [3,4-d]pyrimidin-4-one; and
1-isopropyl-6-[1-(3-phenoxyazetidin-1-yl)ethyl]-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one;
or a pharmaceutically acceptable salt thereof.

### Claim 10

A compound of formula I,
or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable vehicle, carrier or diluent.
